Our emerging understanding of the dichotomous roles that EphB4 and ephrinB2 play in head and neck squamous cell carcinoma (HNSCC) poses a significant challenge to rational drug design. This evidence concerns the gene EFNB2 and head and neck squamous cell carcinoma.